期刊文献+

外周血淋巴细胞/单核细胞比值在肝细胞肝癌中的临床意义 被引量:3

Ratio of Lymphocyte to Monocyte in Predicting Recurrence of Patients with Hepatocellular Carcinoma
原文传递
导出
摘要 [目的]探讨肝细胞肝癌(hepatocellular carcinoma,HCC)患者切除术前外周血淋巴细胞/单核细胞的比值(lymphocyteand monocyte ratio,LMR)对HCC患者术后复发的影响。[方法]回顾性分析接受HCC根治性切除术的患者119例,使用X-tile软件估算LMR对于术后复发的最佳决定值,根据该值将119例入组患者分为两组。用Kaplan-Meier法绘制生存曲线,Log-rank检验评估LMR在全部患者人群以及多种低危风险组中的价值。单因素Cox回归模型分析术前各临床参数对于术后复发的影响,有统计学意义的术前单因素进入Cox回归模型进行多因素分析。[结果]截止2015年7月,119例患者中位随访时间42.30个月,共有56例患者发生复发,占总入组人数的47.06%。X-tile计算得到的最佳切点为4.84,119例入组患者分为LMR≤4.84者72例(60.50%),LMR〉4.84者47例(39.50%)。单因素分析显示卫星灶(P=0.032)和术前LMR≤4.84(P=0.004)是术后无瘤生存率的影响因素。多因素分析显示卫星灶和LMR分别是预测术后肿瘤复发的独立危险因子(卫星灶:OR=1.90,95%CI:1.07~3.36,P=0.028;LMR:OR=0.41,95%CI:0.22~0.74,P=0.003)。对AFP阴性(≤400ng/ml)以及BCLC 0+A期的早期肝癌两个低复发风险亚组,LMR依然是一个具有显著意义的复发评估指标(P均〈0.05)。LMR与肿瘤的血管侵犯显著相关(P=0.020)。[结论]LMR是一个简便、高效、易检测、低成本的HCC切除术后早期复发预测指标,LMR≤4.84的HCC患者术后早期复发风险显著增加。 [Objective] To investigate the application of the ratio of lymphocyte to monocyte(LMR)in predicting recurrence of patients with hepatocellular carcinoma(HCC) after curative resection.[Methods] The clinical data of 119 patients undergoing curative resection were retrospectively reviewed. X-tile software was used to evaluate the optimal cutoff value for LMR,and the entire cohort of patients were stratified into two groups according to this optimal cutoff value. Difference of recurrence rates between these two groups in entire cohort or low-recurrence-risk subgroups were compared with Kaplan-Meier curves and Log-rank tests. Univariate and multivariate regression analyses were performed to determine the independent predicting factors for tumor recurrence. [Results] The median follow-up time was 42.30 months,and 56 patients encountered recurrence during this period. LMR of 4.84 was set as the optimal cutoff value according to X-tile and patients were stratified into high-risk and low-risk groups based on this value. Univariate regression analysis revealed that satellite lesion(P=0.032) and LMR(P=0.004) were significantly associated with the tumor recurrence. Furthermore,multivariate regression analysis showed that satellite lesion(OR=1.90,95%CI:1.07~3.36,P=0.028) and LMR(OR=0.41,95%CI:0.22~0.74,P=0.003) were the independent indictors for predicting recurrence. LMR retained its prognostic value in low AFP and early-HCC subgroups(all P〈0.05). [Conclusion] LMR is a convenient and effective prognostic indicator of recurrence prediction in HCC patients after curative resection,and HCC patients with a LMR≤4.84 have higher risk of tumor recurrence.
作者 沈晓燕 李婷婷 童海江 SHEN Xiao-yan;LI Ting-ting;TONG Hai-jiang(The Shaoxing Second Hospital,Shaoxing 312000,China)
机构地区 绍兴第二医院
出处 《肿瘤学杂志》 CAS 2018年第8期774-778,共5页 Journal of Chinese Oncology
关键词 肝细胞肝癌 淋巴细胞 单核细胞 复发 hepatocellular carcinoma lymphocyte monocyte recurrence
  • 相关文献

参考文献3

二级参考文献213

  • 1Jian-Yong Lei,Wen-Tao Wang,Lu-Nan Yan.“Metroticket” predictor for assessing liver transplantation to treat hepatocellular carcinoma:A single-center analysis in China's Mainland[J].World Journal of Gastroenterology,2013,19(44):8093-8098. 被引量:5
  • 2GeertuDeli,Can-HaoJin,RongMu,SongYang,YueLiang,DeChen,MasatoshiMakuuchi.Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues[J].World Journal of Gastroenterology,2005,11(7):960-963. 被引量:19
  • 3王洪海,任宁,张辉,叶青海,孙惠川,王鲁,谭云山,钦伦秀.联合检测VEGF、PD-ECGF和PCNA表达预测肝细胞癌术后复发及预后[J].中国临床医学,2005,12(3):448-451. 被引量:7
  • 4Muriel Mathonnet,Bernard Descottes,Denis Valleix,Francois Labrousse,Yves Denizot.VEGF in hepatocellular carcinoma and surrounding cirrhotic liver tissues[J].World Journal of Gastroenterology,2006,12(5):830-831. 被引量:5
  • 5F. Y.Yao,L.Xiao,N. M.Bass,R.Kerlan,N. L.Ascher,J. P.Roberts.Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF‐Expanded Criteria Based on Preoperative Imaging[J].American Journal of Transplantation.2007(11)
  • 6Kang-jie Chen,Lin Zhou,Hai-yang Xie,Taki-Eldin Ahmed,Xiao-wen Feng,Shu-sen Zheng.Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection[J]. Medical Oncology . 2012 (3)
  • 7Pierre-Alain Clavien,Mickael Lesurtel,Patrick MM Bossuyt,Gregory J Gores,Bernard Langer,Arnaud Perrier.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncology . 2012 (1)
  • 8Josep M. Llovet,Jordi Bruix.Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology . 2003 (2)
  • 9Dmitry I. Gabrilovich,Srinivas Nagaraj.Myeloid-derived suppressor cells as regulators of the immune system[].Nature Reviews Immunology.2009
  • 10Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)

共引文献110

同被引文献39

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部